WO1996009389A3 - Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein - Google Patents

Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein Download PDF

Info

Publication number
WO1996009389A3
WO1996009389A3 PCT/SI1995/000022 SI9500022W WO9609389A3 WO 1996009389 A3 WO1996009389 A3 WO 1996009389A3 SI 9500022 W SI9500022 W SI 9500022W WO 9609389 A3 WO9609389 A3 WO 9609389A3
Authority
WO
WIPO (PCT)
Prior art keywords
escherichia coli
recombinant
mif
purification
expression
Prior art date
Application number
PCT/SI1995/000022
Other languages
French (fr)
Other versions
WO1996009389A2 (en
Inventor
Francky Bojana Mozetic
Andrej Francky
Original Assignee
Francky Bojana Mozetic
Andrej Francky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Francky Bojana Mozetic, Andrej Francky filed Critical Francky Bojana Mozetic
Priority to AU34895/95A priority Critical patent/AU3489595A/en
Publication of WO1996009389A2 publication Critical patent/WO1996009389A2/en
Publication of WO1996009389A3 publication Critical patent/WO1996009389A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

According to the known cDNA sequence we used the PCR (polymerase chain reaction) technique to isolate a gene encoding human MIF from uterus endometrium The PCR product was cloned in the Escherichia coli plasmid vector pUC 19 and the nucleotide sequence was confirmed. We were able to successfully express human MIF in the bacteria Escherichia coli by use of the pKP 1500 expression plasmid. The recombinant protein accumulated intracellularly in soluble form, comprising more then 30 % of total cell protein. We have designed an original two step procedure where protein purification was accomplished by gel filtration and ion exchange chromatography. The purified recombinant MIF was used to immunise a rabbit and antibodies obtained were used for MIF detection in human tissues by immunohistochemical techniques.
PCT/SI1995/000022 1994-09-19 1995-09-18 Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein WO1996009389A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34895/95A AU3489595A (en) 1994-09-19 1995-09-18 Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9400363A SI9400363A (en) 1994-09-19 1994-09-19 Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
SIP-9400363 1994-09-19

Publications (2)

Publication Number Publication Date
WO1996009389A2 WO1996009389A2 (en) 1996-03-28
WO1996009389A3 true WO1996009389A3 (en) 1996-05-23

Family

ID=20431460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SI1995/000022 WO1996009389A2 (en) 1994-09-19 1995-09-18 Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein

Country Status (3)

Country Link
AU (1) AU3489595A (en)
SI (1) SI9400363A (en)
WO (1) WO1996009389A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
JP2008534502A (en) 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ Thienopyridinone derivatives as inhibitors of macrophage migration inhibitory factor
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011301A1 (en) * 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
WO1992019727A1 (en) * 1991-04-26 1992-11-12 National Institutes Of Health Isolation of macrophage migration inhibition factor from ocular lens and dna which encodes the factor
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011301A1 (en) * 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
WO1992019727A1 (en) * 1991-04-26 1992-11-12 National Institutes Of Health Isolation of macrophage migration inhibition factor from ocular lens and dna which encodes the factor
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
J. BERNHAGEN ET AL: "MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia", NATURE, vol. 365, 21 October 1993 (1993-10-21), LONDON GB, pages 756 - 759 *
J. BERNHAGEN ET AL: "Purification ,bioactivity, and secondary structure analysis of mouse and human Macrophage Migration Inhibitory Factor (MIF)", BIOCHEMISTRY, vol. 33, no. 47, 29 November 1994 (1994-11-29), EASTON, PA US, pages 14144 - 14155 *
MAMORU SUZUKI ET AL: "Crystallization and a preliminary X-ray diffraction stydy of Macrophage Migration Inhibitory Factor from human Lymphocytes", JOURNAL OF MOLECULAR BIOLOGY, vol. 235, no. 3, pages 1141 - 1143 *
TAKEYOSHI MIKI ET AL: "Construction of a plasmid vector for the regulatable high level expression of eukaryotic genes in Escherichia coli : an application to overproduction of chicken lysozyme", PROTEIN ENGINEERING, vol. 1, no. 4, ENGLAND GB, pages 327 - 332 *
TOSHIFUMI MIKAYAMA ET AL: "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, WASHINGTON US, pages 10056 - 10060 *
V. PARALKAR ET AL: "Cloning the human gene for Macrophage Migration Inhibitory Factor (MIF)", GENOMICS, vol. 19, no. 1, 1 January 1994 (1994-01-01), pages 48 - 51 *
W. Y. WEISER ET AL: "Molecular cloning of a cDNA encoding a human Macrophage Migration Inhibitory Factor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, WASHINGTON US, pages 7522 - 7526 *

Also Published As

Publication number Publication date
AU3489595A (en) 1996-04-09
WO1996009389A2 (en) 1996-03-28
SI9400363A (en) 1996-08-31

Similar Documents

Publication Publication Date Title
Goebel et al. Cloning and functional characterization of the plasmid-encoded hemolysin determinant of Escherichia coli
Lomax et al. Isolation and characterization of light-regulated phycobilisome linker polypeptide genes and their transcription as a polycistronic mRNA
EP0211148B2 (en) Mature human leukozyte interferons, process for their bacterial production, intermediates therefor and compositions containing them
AU6633186A (en) Construction of an IgG binding protein to facilitate downstream processing using protein engineering
Belev et al. A fully modular vector system for the optimization of gene expression in Escherichia coli
EP1559776A3 (en) Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system and promoters and terminators for use therein
EP0088195A3 (en) Messenger rna, production and use thereof
ES8602119A1 (en) Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor.
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
EP0169146A3 (en) Monoclonal antibodies directed against the cellular receptor of human rhinovirus
IE61773B1 (en) Novel lymphokine related peptides
Yasueda et al. High-level direct expression of semi-synthetic human interleukin-6 in Escherichia coli and production of N-terminus met-free product
CA2102702A1 (en) Vitamin K-Dependent Carboxylase
IE852681L (en) Monoclonal antibodies for cancer
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO1996009389A3 (en) Recombinant macrophage migration inhibitory factor; expression in escherichia coli and purification of recombinant protein
WO1995030001A3 (en) Novel p-selectin ligand protein
NO174631B (en) Method of Preparation of Homogeneous Recombinant Immune Interferon Fragment, Replicable Vector and Microorganism
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
JPH0139756B2 (en)
Sarvas et al. A precursor form of the penicillinase from Bacillus licheniformis
Chang et al. Expression of eukaryotic genes in B. subtilis using signals of pen P
EP0811685A3 (en) Human platelet-derived growth factor receptors
CA2002833A1 (en) Interferon-gamma binding proteins
EP0072541A3 (en) Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 809025

Date of ref document: 19970319

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase